Description

Risuteganib Hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide engineered to modulate integrin receptor function. It targets three integrin heterodimers implicated in dry age-related macular degeneration (AMD), helping downregulate oxidative stress and restore retinal homeostasis .

Preclinical studies demonstrate that Risuteganib protects retinal pigment epithelial (RPE) cells from oxidative damage induced by toxins like hydroquinone by reducing reactive oxygen species (ROS) levels, stabilizing mitochondria, improving bioenergetics, and inducing protective proteins such as heme oxygenase-1.

Clinical and preclinical evidence highlights its anti-inflammatory and mitochondrial-stabilization properties, which may prevent cellular apoptosis and support visual function in AMD models. Early clinical trials show visual acuity improvement in intermediate dry AMD with a strong safety profile.

Manufactured under GMP standards, Risuteganib HCl offers high reproducibility and consistency, critical for pricing and excellence in laboratory research.

Risuteganib Hydrochloride Product Specifications

Risuteganib Hydrochloride Mechanism of Action & Research Applications

Mechanism of Action
Risuteganib is an RGD-class anti-integrin peptide that modulates integrins involved in retina health, including ?v?3, ?v?5, and ?5?1, helping to restore retinal homeostasis by reducing cellular oxidative stress and stabilizing mitochondrial function.

Research Applications

• Dry AMD Models: Study protective effects on RPE cells under oxidative stress and evaluate integrin-mediated stabilization pathways.

• Oxidative Injury Protection: Use in assays involving hydroquinone or other stressors to assess ROS mitigation and mitochondrial resilience.

• Mitochondrial & Anti-inflammatory Research: Investigate pathways involving heme oxygenase-1 induction and integrin suppression.

• Comparative Mechanistic Studies: Compare with other AMD-targeted peptides or antioxidants for efficacy profiling.

• Drug Development Screening: Use as a lead candidate for retinal homeostasis agents in preclinical pipeline work.

Risuteganib Hydrochloride Development & Formulation Notes

• Reconstitution: Dissolve in DMSO to make concentrated stock (e.g., 10 mM), then dilute into buffer; heat (37 °C) or sonicate to assist solubilization.

• Storage & Stability: Keep stocks frozen at ? –20 °C; avoid repeated freeze-thaw cycles for potency preservation.

• Assay Considerations: When used in RPE cell culture, establish dose-response curves for cytoprotection vs. oxidative exposure; include mitochondrial and ROS endpoints.

  

Disclaimer

Risuteganib Hydrochloride is strictly for laboratory research use only. It is not a drug, diagnostic, or therapeutic product and is not approved for human or veterinary use. Handle according to institutional safety protocols. Users are responsible for appropriate use and regulatory compliance.

Risuteganib Hydrochloride Packaging & Availability

• Standard Packs: 1 mg, 5 mg, 10 mg—suitable for lab-scale studies.

• Bulk / Wholesale: Multi-gram lots with batch continuity and scheduled delivery for long-term projects.
  Each lot includes a Certificate of Analysis (CoA) outlining purity, identity, and handling guidelines.

Quality Assurance

Manufactured under GMP conditions with documented testing for identity, purity, and stability. Optional endotoxin and sterility documentation available on request for institutional or regulatory use.

Custom Services

• Custom Labeling and Aliquoting tailored for your lab’s workflows.

• Formulation Support—buffers, solvents, lyophilization protocols.

• Stability Study Design—consulting for storage and shipping conditions.

• Experimental Planning Assistance for AMD and oxidative stress studies.

Keywords

Risuteganib hydrochloride; RGD peptide; anti-integrin; oxidative stress; retinal homeostasis; dry AMD research; RPE protection; mitochondrial stabilization; GMP peptide; research-use-only.